|
Safe, effective, and ethical administration
|
|
Knowledge, technical skill, and judgement required
|
|
Ongoing maintenance of competence
|
|
Systematic, ongoing, and dynamic part of the nursing process
|
|
Determining status of goals and outcomes of care
|
|
Monitoring patient's response to drug therapy (Therapeutic, expected, toxic responses)
|
|
Clear, concise documentation
|
|
Fastest
|
Liquids, elixirs, syrups
|
|
Suspension solution
|
|
|
Powders
|
|
|
Capsules
|
|
|
Tablets
|
|
|
Coated tablets
|
|
|
Slowest
|
Enteric-coated tablets
|
|
The metabolism of a drug and its passage from liver into circulation
|
|
Oral drugs are absorbed from intestinal lumen into mesenteric blood system, and go to the liver by means of portal vein
|
|
Once in the liver, it is metabolized by P450 enzyme system and passed into general circulation
|
|
If large amount of drug is metabolized to an inactive form, then less is available in circulation (high first-pass effect)
|
|
Means that most drugs have bioavailability of <100%, whereas same drug given IV is 100% bioavailable because it has not been metabolized by the liver
|
|
Receptor Interaction
Drug reacts with a site on the surface of a cell or tissue to elicit/block a physiological response
|
|
Receptor agonist
Elicit response from the cell
|
|
Receptor antagonist
Do not elicit response (block usual physiological response)
|
|
Enzyme interaction
Drug inhibits/alters physiological response of enzyme; fools cell to attach to it VS its targeted cells
|
|
Non-specific interaction
Drugs interfere with or chemically alter cellular/metabolic processes
|
|
Many drugs pass into breast milk
|
|
Lower than in maternal circulation
|
|
Depends on drug properties (lipid solubility, concentration, etc.)
|
|
Must consider the harm-benefit ratio
|
|
<38 weeks gestation
|
Premature or preterm infant
|
|
<1 month
|
Neonate or newborn infant
|
|
1month - 11months
|
infant
|
|
1 year - 12 years
|
Child
|
|
13 years - 19 years
|
Adolescent
|
|
Important to weigh in kg as doses often weight and/or body surface area based
|
|
|
Pharmaceutics
Science of preparing and dispensing drugs, including dosage form and design (ie. Tablets, patches, capsules, injections)
|
|
Pharmacokinetics
What the body does to the drug (Absorption, distribution, metabolism, excretion)
|
|
Pharmacodynamics
What the drug does to the body (biochemical and physiological interactions)
|
|
Pharmacotherapeutics
Use of drugs and clinical indications for drugs to prevent and treat disease
|
|
Pharmacognosy
Study of natural plant and animal drug sources
|
|
I. Pharmaceutical Phase
Disintegration of dosage form
|
|
II. Pharmacokinetic Phase
Absorption, distribution, metabolism, excretion
|
|
III. Pharmacodynamic Phase
Drug-receptor interaction
|
|
80% of drugs are PO
|
|
Absorption
Process of drug leaving the site of administration and becoming available
|
|
Distribution
Drugs are distributed throughout body by blood stream
|
|
Biotransformation: Primarily Liver (also skeletal muscle, kidney, plasma, lungs)
Process of transforming a drug into inactive metabolite (more soluble compound)
|
|
Cytochrome P-450 enzymes most responsible for biotransformation
|
|
Hepatic biotransformation varies (genetics, diseases, other drugs, etc.)
|
|
Elimination of drugs from body
|
|
Excrete through kidney (main organ)
|
|
Other routes: liver, bile feces, lungs, saliva, sweat, breast milk
|
|
Food and Drug Regulations (Schedule F)
Lists drugs that must be sold by prescription
|
|
First trimester generally period of greatest danger
|
|
Transfer to fetus primarily by diffusion across placenta and some active transport
|
|
Factors that contribute to safety include drug properties, gestational age, and maternal factors
|
|
65 years or older
|
|
Polypharmacy
Consumes 20-40% of Rx drugs, 40% OTC drugs |
|
Risk of drug interactions
|
|
Refer to table 4.4 p. 68-69 for problematic drugs
|
|
Right drug
|
|
Right dose
|
|
Right time
|
|
Right route
|
|
Right patient
|
|
Right reason
|
|
Right documentation
|
|
Right evaluation
|
|
Right patient education
|
|
Right to refuse
|
|
Chemical Name
Drug's chemical composition and molecular structure
|
|
Generic Name
Name given by Health Canada under FDA and FDR
|
|
Trade name
Drug has registered trademark; use of name restricted by drug's patent owner
|
|
Sublingual
|
|
Buccal
|
|
Rectal
|
|
Intravenous
|
|
Intranasal
|
|
Transdermal
|
|
Vaginal
|
|
Intramuscular
|
|
Subcutaneous
|
|
Inhalation
|
|
Time it takes for one half of the original amount of a drug to be eliminated from the body
|
|
Metabolism and elimination affect the half-life of a drug
|
|
Useful for determining 'steady state'
|
|
Amount of drug eliminated is equal to amount absorbed at each administration
|
|
Steady-state is desired to achieve a therapeutic effect over time
|
|
Longer half-life = longer it takes to reach steady state
|
|
Onset
Time it takes to reach minimum effective concentration
|
|
Peak
Occurs when drug reaches highest blood or plasma concentration
|
|
Duration
Length of time drug has a pharmacologic effect
|
|
Teratogenic
Disturb fetal/embryo development
|
|
Mutagenic
Changes genetic material
|
|
Carcinogenic
Cancer-causing
|
|
Food and Drugs Act
|
- Protect consumer from drugs that are contaminated, adulterated, or unsafe for use.
- Addresses drugs taht are labeled falsely and those with misleading/deceptive labels |
|
Controlled Drugs and Substances Act
|
- Addresses possession, sale, manufacture, disposal, production, import, export, and distribution of certain drugs
|
|
Restricted Access Drug
- Must ask pharmacist (insulin, loperamide)
|
|
Pharmacy Only
ie. Antihistamines, ulcer meds
|
|
General Retail
ie. Acetaminophen, nicotine gum
|
|
Criteria for OTC Status
- Consumer must easily diagnose condition and monitor effectiveness
- Drug should have: favourable adverse affect, profile, limited drug interaction profile, low misuse potentional - Drug should be easy to use and easy to monitor |
No comments yet.
Cheatography n. The art of mapping complex subjects into clear, instantly navigable reference guides.